Regeneron Pharmaceuticals | 460.1300 / +2.39% |
News
- FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
03/04/2021 / 07:00 - GlobeNewswire - EMA extends use advice for Regeneron COVID mix
02/26/2021 / 12:28 - TeleTrader - Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results
02/25/2021 / 22:05 - GlobeNewswire - Europe closes lower amid recovery uncertainties
02/25/2021 / 17:31 - TeleTrader - Regeneron: COVID cocktail has clear efficacy
02/25/2021 / 14:13 - TeleTrader - Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results
02/25/2021 / 13:30 - GlobeNewswire - Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
02/24/2021 / 13:00 - GlobeNewswire - Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
02/23/2021 / 14:00 - GlobeNewswire - FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
02/22/2021 / 19:00 - GlobeNewswire - ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director
02/18/2021 / 13:00 - GlobeNewswire - Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021
02/16/2021 / 22:01 - GlobeNewswire - The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
02/12/2021 / 07:00 - GlobeNewswire - FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
02/09/2021 / 23:15 - GlobeNewswire - Regeneron to deliver 750K therapy doses to US by July
02/05/2021 / 15:53 - TeleTrader - Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors
02/05/2021 / 15:00 - GlobeNewswire